INTRODUCTION
Protein C is a vitamin K-dependent plasma protein and is the zymogen of a serine protease, activated protein C. Unlike the vitamin K-dependent clotting factors, activated protein C inhibits clot formation. This anticoagulant activity appears to involve the selective inactivation of Factors V (Va) (1) and VIII (VIIIa) (2) . Anticoagulant activity is dependent on the proteolytic active site because incorporation of diisopropylphosphate into the active site totally blocks this activity (3).
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Evidence for the activation of protein C in vivo has recently been presented by Marlar and Griffin (4) who showed that a group of patients lacking an inhibitor to activated protein C exhibited simultaneous Factor VIII and Factor V deficiency. We have now shown the presence of an endothelial cell surface cofactor for thrombin-catalyzed protein C activation that accelerates the thrombin-catalyzed activation of protein C at least 20,000-fold (5, 6 ). These observations provide evidence for protein C activation in humans and provide a plausible mechanism by which this activation can occur.
In addition to its function as an anticoagulant, activated protein C has been shown by Zolton and Seegers (7, 8) to enhance fibrinolysis, at least in part, by lowering the levels of fibrinolytic inhibitors. Our studies (9) have confirmed that fibrinolytic activity can be generated both in vivo and in vitro in response to activated protein C. We have recently described a quantitative method for using lysine-agarose to assay plasminogen activator levels (10) . We have now used this assay to further characterize the in vivo fibrinolytic state induced by activated protein C.
METHODS
Reagents. Bovine blood was the generous gift of the Comett Packing Company, Oklahoma City, Okla. QAESephadex Q-50, SP-Sephadex C-50, porcine heparin grade II, and soybean trypsin inhibitor were purchased from Sigma Chemical Co., St. Louis, Mo. D-valine-leucine-lysine-pnitroanilide (S2251) was purchased from Ortho Pharmaceuticals, Raritan, N. J. Benzamidine HC1 was purchased from Aldrich Chemical Co., Milwaukee, Wis. Acrylamide of electrophoresis grade was purchased from Eastman Laboratory and Specialty Chemicals, Rochester, N. Y. All other reagents were of the highest grade commercially available.
Preparation of affinity columns. Lysine (11) and heparin (12) were coupled to Biogel agarose A 15 (Bio-Rad Laboratories, Richmond, Calif.) following cyanogen bromide (CNBr) activation (13) .
Preparation of proteins. All proteins were of bovine origin. Protein C (14, 15) and prothrombin (16) were isolated by published methods. Thronmbin was prepared by activation of prothrombin with Factor Xa, Factor Va, phospholipid, and Ca++ as described (16) . Bovine and canine plasminogen were prepared by the method of Deutsch and Mertz (11) . Protein C (20 mg, 3 mg/ml) was activated with bovine thrombin (1 mg, 0.15 mg/ml) in 2 mM Tris buffer, pH 7.4, containing 50 mM NaCl at 4°C for 16 h. The activation mixture was then brought to pH 6.0 by the addition of 2(Nmorpholine) ethane sulfonic acid to a final concentration of 20 mM. The mixture was then chromatographed on a 0.9
x 60 cm sulfopropyl Sephadex C-50 column equilibrated in 50 mM NaCl, 1 mM benzamidine, 20 Fibrinolysis studies in whole blood clots. Whole blood (2.5 ml) was collected, added to a 17 x 100-mm polystyrene tube containing 280 ,ul of 3.8% citrate, pH 5.5, and mixed immediately on a Vortex mixer. To this was added 10 ,ug 1251-human fibrinogen with a specific activity of -167 ,iCi/mg and the blood again mixed. The blood was clotted with 5 U bovine thrombin in 100 Ail of 0.15 M NaCl, 20 mM Tris HC1, pH 7.4. The thrombin was added while vortexing the blood. The blood was allowed to clot at room temperature for 5 min and then the clot was freed from the wall of the tube by rimming the clot with a round wooden applicator stick. The clots were then incubated in a 370C water bath and at 30 min, 1 h, and hourly intervals thereafter, 100-,ul samples of serum were withdrawn from around the clot and placed in 400-,ul plastic microcentrifuge tubes (Bio-Rad Laboratories).
The tubes were centrifuged for 5 min in a Beckman microfuge B. 30 ,ul serum was then removed from above the pellet of shed erythrocytes, placed in a Biovial, and 1251-fibrin-split product content was determined by counting the sample in a Beckman gamma counter. Visible clot lysis was monitored by gently tipping the tubes at hourly intervals. Lysis was judged to be complete when the organized clot was no longer visible.
Plasminogen activator assay. Plasminogen activator activity in canine plasma was measured using lysine-agarose and bovine fibrin agar plates as described for human plasma (10) . Using this method, canine plasma was passed through lysine-agarose columns and the adsorbed plasminogen activator activity was eluted from the columns with ammonium thiocyanate-containing buffer. Plasminogen activator activity was then quantitated by measuring the conversion of plasminogen to plasmin on bovine fibrin agar plates. Preparation ofconcentrated plasminogen activator. Concentrated preparations of lysine-adsorbable plasminogen activator were made from blood obtained 5 min after the intravenous injection of 5 ,ug protein Ca per milliter plasma volume. Benzamidine and EDTA were added to citrated canine plasma as described (10) , and 10 ml of plasma was chromatographed on a 0.9 x 10-cm lysine-agarose column. 1222 P. C. Comp and C. T. Esmon
After washing, the plasminogen activator was eluted from the column as described at a rate of 3 ml/h. 
RESULTS
Effect of activated protein C on whole blood clot lysis. The intravenous administration of activated protein C resulted in an increase in the rate at which whole blood clots lysed (Fig. 1 mained stable during and after the experirment, suggesting that internal hemorrhage did not occur. Neutralization of protein Ca before clot formation. As noted above, optimal lytic response required intravenous infusion of protein Ca. Addition of equivalent levels of protein Ca to citrated blood in vitro gave a comparatively small increase in the rate of clot lysis. This suggested that protein Ca, itself, might not be necessary in the clotted blood for the enhancement of lysis to occur. To examine this possibility, we administered protein Ca intravenously to a dog, drew blood from the animal, and then added sufficient rabbit IgG directed against protein C to neutralize the protein Ca (Fig. 4) . The dog blood treated with the IgG had a rate of clot lysis very similar to the untreated blood. The IgG did not affect the rate of lysis of preprotein Ca control blood clots. This suggested that protein Ca was not having a direct effect in the formed clot but in the circulation.
Effect ofprotein Ca on circulating lysine-adsorbable plasminogen activator levels. Because protein Ca did not cause clot lysis directly, we examined the canine plasma to determine if plasminogen activator activity was generated as a result of protein Ca injection. Specifically, we looked for the appearance of lysineadsorbable plasminogen activator activity in the dog's plasma. Radcliffe and Heinze (19) have found that human lysine-adsorbable plasminogen activator activity increases after exercise and we (10) have found CLOT INCUBATION (hours) FIGURE 4 Effect of neutralizing protein Ca on the rate of clot lysis. A dog was injected with 5 ,ug protein Ca per milliliter plasma volume. Blood was drawn 5 min after protein Ca administration and was divided into 2 aliquots. One aliquot had sufficient rabbit IgG directed against protein C added to neutralize protein Ca activity (0), while the second had the same volume of Tris-saline added (U). Both samples were clotted, as was a sample of canine blood taken before protein Ca injection (A). The addition of IgG alone to canine blood did not change the rate ofclot lysis (data not shown).
Two other animals showed similar results under the same conditions.
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P. C. Comp and C. T. Esmon elevated levels in humans with cirrhosis and following venous occlusion and exercise. The levels of lysineadsorbable plasminogen activator were measured before and after protein Ca administration to a dog (Fig.  5) . A fivefold increase in lysine-adsorbable plasminogen activator was observed 5 min after protein Ca injection. The lysine-adsorbable plasminogen activator level decreased over the following 30 min. When the equivalent level of protein Ca was added to citrated whole blood, no elevation of lysine-adsorbable plasminogen activator was observed. We wished to determine if a dose-response relationship existed between the level of protein Ca administered to the dog and the level of lysineadsorbable plasminogen activation generated, (Fig. 6) . A positive dose-response relationship did exist. Within the concentration range tested, the response was not saturated. The highest dose used, 10 ,ug/ml, resulted in the complete lysis of the clots in 25-30 min and a 4.8-fold rise in the plasminogen-activator level.
Whereas the increase in lysine-adsorbable plasminogen activator following protein Ca administration suggested that this plasminogen activator might be involved in the increased rate ofclot lysis observed, any number of other plasminogen activators or profibrinolytic activities might also be generated by the protein Ca. To determine if the levels of lysine-adsorbable plasminogen activator we observed were sufficient to give these increases in the rate of clot lysis, concentrated lysine-adsorbable plasminogen activator (made from the plasma ofa dog infused with protein Ca) was added to normal canine blood in vitro before clot formation (Fig. 7) . The canine blood had 0.06 U intrinsic activator activity per milliliter and had a relatively slow rate of fibrin-split product release. Lysineadsorbable plasminogen activator was added to the blood at levels approximating those seen after protein Ca infusion. The exogenous plasminogen activator produced whole blood clot lysis rates in vitro comparable to those observed following protein Ca administration in vivo.
Estimation of molecular weight of plasminogen activator by SDS gel electrophoresis. Lysine-adsorbable plasminogen activator was obtained from plasma samples prepared before and after injection of3 gg protein Ca per milliliter canine plasma volume. The molecular weight of the plasminogen activator was determined on SDS gels as described (Methods). The molecular weight was estimated at 70,000-72,000 (Fig.  8) . This value was in agreement with estimates made using Ultrogel AcA34 of 62,000-66,000.
Neutralization ofprotein Ca added to blood in vitro. The generation of plasminogen activator could be due to either a direct or indirect effect of protein Ca on plasminogen activator production. The indirect mechanism could involve formation of a product in blood, which then leads to the release/generation of plasminogen activator. To examine the latter possibility, we added protein Ca to blood in vitro and then neutralized the protein Ca with antibodies before reinjection into the dog (Fig. 9) injected into the dog (Fig. 10) The origin of the lysine-adsorbable plasminogen activator is unknown. However, the molecular weight of 70,000 suggests it may be related to vascular plasminogen activator described by others (20, 21) . Vascular plasminogen activator is released into the blood by various physiologic events, including ischemia (22) , pyrogenemia (23) , and physical exercise (24) . The administration of protein Ca causes the elevation of plasminogen activator activity without changing the animals' pulse, respiratory rate, blood pressure, or temperature. Therefore, it is doubtful hypotension or shock play a role in the action of protein Ca.
Protein Ca does not appear to directly release plasminogen activator from the vasculature. Our preliminary results indicate that when oxygenated buffer containing protein Ca is used to perfuse isolated dog tissues, little or no plasminogen activator activity is released from the blood vessel walls. However, when protein Ca is added to blood in vitro with subsequent neutralization of the protein Ca with antibodies, the rate of clot lysis is increased when the blood is reinjected into the animal. The addition of protein Ca to plasma alone is sufficient to generate the fibrinolytic activity, but the effect is more marked when protein Ca is added to a mixture of plasma and blood cells. These findings suggest that protein Ca generates a secondary messenger, or family of messengers, which in turn cause the elevation of circulating plasminogen activator activity.
